Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on June 13, 2011, regarding an event that occurred on June 9, 2011. The filing addresses corporate governance and executive compensation matters.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to executive compensation adjustments.
Material Changes
The primary material change reported is the promotion of Akshay K. Vaishnaw, M.D., Ph.D., to Senior Vice President and Chief Medical Officer. In connection with this promotion, the following compensation changes were approved:
- Base Salary Increase: Annual base salary increased from $359,805 to $385,000.
- Stock Option Grant: Award of options to purchase 100,000 shares of common stock.
- Exercise Price: Set at $9.30 per share, reflecting the last reported sale price on June 9, 2011.
- Vesting Schedule: 25% vests on June 9, 2012, with an additional 6.25% vesting at the end of each successive three-month period thereafter until the fourth anniversary of the grant date.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on business strategy, or discussion of risks and contingencies. The document is strictly limited to the announcement of the executive appointment and associated compensatory arrangements.
Key Facts for Investor Verification
- Confirmation of Dr. Vaishnaw's tenure and prior role as Senior Vice President of Clinical Research since December 2008.
- Verification of the stock option exercise price ($9.30) against the market price on June 9, 2011.
- Understanding of the four-year vesting schedule for the 100,000 share option grant.
- Assessment of the impact of the salary increase on the company's overall compensation expense, though specific totals are not provided in this filing.